A New Discovery in the War Against Coronavirus

Business, National News, Technology
Reading Time: 2 minutes

Moleculin Biotech, Inc., which is a clinical stage pharmaceutical company with a broad portfolio of drug candidates, announced  this week that independent research found 2-deoxy-D-glucose (“2-DG”) to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing.

This is a significant discovery. Researchers at the University of Frankfurt in Germany annonced the findings in their article submitted to NatureResearch on March 11, 2020 (https://www.researchsquare.com/article/rs-17218/v1). The authors noted that inhibiting glycolysis with non-toxic concentrations of 2-DG “completely prevented SARS-CoV–2 replication in Caco–2 cells.  Glycolysis is a process by which cells convert glucose into energy and infected (host) cells are induced by viruses to dramatically increase their dependence on glycolysis.  2-DG inhibits glycolysis because, although it appears to cells to be glucose, it is in fact a decoy that cannot be converted into energy.”

Moleculin’s drug candidate, WP1122, is referred to as a “‘prodrug’ of 2-DG whereby chemical elements are added to 2-DG to improve its delivery in vivo.  Once administered, these added elements are removed by normal metabolic processes and what remains is 2-DG. As a result, 2-DG is the active compound in WP1122.  In chemical terms, it is referred to as the active “moiety” (subpart) of WP1122.”

“This is the breakthrough we were looking for, only it came from an unexpected source,” stated Walter Klemp, Chairman and CEO of Moleculin. “Normally, we wouldn’t have access to data like this until it is published, but the willingness of the authors to pre-release this data will help support our development of WP1122 for treating COVID-19.”

Dr. Don Picker, Chief Science Officer of Moleculin went on to state that “2-DG is what we call the ‘active moiety’ in WP1122.  The problem with 2-DG is that it is metabolized by the body too quickly, so you can’t get enough concentration in human tissues and organs to be therapeutic.  Therefore, even though 2-DG is active against a range of viruses, including SARS-CoV-2, it isn’t useful as a clinical therapy because it’s too rapidly metabolized.  WP1122 appears to solve this problem because it is a ‘prodrug’ of 2-DG.  Its structure enables it to achieve much higher tissue/organ concentrations than 2-DG alone, but once it’s in the cell, it metabolizes into the exact same 2-DG that is so effective in vitro.”

Moleculin’s Chief Medical Officer – New Projects, Dr. Sandra Silberman chimed in: “The FDA has cleared the way for very rapid development of COVID-19 therapies, so we should be able to move WP1122 into the clinics on an expedited basis.  Fortunately, it has a very good safety profile in mice.  We are in the process of demonstrating safety in additional species before submitting our IND (Investigational New Drug application).  Since it has better drug-like properties than 2-DG, WP1122 also actually works better in the animal tumor models we have been studying. We think this bodes well for its potential as a more potent drug than 2-DG as an antiviral agent against coronavirus.”

Share This: